Retatrutide vs Tirzepatide
Retatrutide vs tirzepatide compared: how the dual and triple incretin agonists differ in mechanism, status, and tracking. Educational only — not medical advice.
GLP-1 / GIP / glucagon agonist · Metabolic
An investigational once-weekly agonist that acts on three hormone receptors at once — GLP-1, GIP, and glucagon — and is studied in the context of appetite and metabolic regulation.
Full Retatrutide page →GIP/GLP-1 dual agonist · Metabolic
A long-acting dual GIP and GLP-1 receptor agonist that mimics two gut hormones to regulate appetite and blood sugar, best known as the active ingredient in widely prescribed metabolic medications.
Full Tirzepatide page →At a glance
Key differences
Both are next-generation incretin agonists used in metabolic contexts, with the main difference being how many receptors they target.
- Tirzepatide is a dual GIP/GLP-1 agonist and is an approved, widely prescribed medication.
- Retatrutide is a triple agonist (GIP, GLP-1, and glucagon) and is, as of this writing, still investigational rather than broadly approved.
- The added glucagon activity is what distinguishes retatrutide's mechanism; trial data is promising but earlier-stage than tirzepatide's.
- Both are once-weekly and titrated, so both reward dose-change tracking.
Which is discussed for which goal?
Tirzepatide is the established option; retatrutide is the more experimental one generating research interest. Status and availability differ significantly, and neither choice is a recommendation — this is educational only and any use should be under a qualified provider.
Tracking either one
Track each weekly dose with its date, log every titration step, weigh in consistently, and note appetite and side effects. The GLP-1 tracking guide applies to both. Read each in detail: Retatrutide and Tirzepatide.
Frequently asked questions
What is the difference between Retatrutide and Tirzepatide?
Retatrutide is glp-1 / gip / glucagon agonist (An investigational once-weekly agonist that acts on three hormone receptors at once — GLP-1, GIP, and glucagon — and is studied in the context of appetite and metabolic regulation) while Tirzepatide is gip/glp-1 dual agonist (A long-acting dual GIP and GLP-1 receptor agonist that mimics two gut hormones to regulate appetite and blood sugar, best known as the active ingredient in widely prescribed metabolic medications) — they differ in class, mechanism, and how they are dosed and tracked.
Is Retatrutide or Tirzepatide better?
Neither is universally "better" — they suit different goals, and this page is educational, not medical advice. The right choice depends on your goals and your provider's guidance.
Can you take Retatrutide and Tirzepatide together?
Some people discuss combining compounds, but stacking changes risks and is a decision for a qualified healthcare provider. Nothing here recommends a combination or dose.
Research & references
For primary research and chemical data, search these databases. Entries here are educational summaries, not citations of specific findings.
Not medical advice
This comparison is educational and does not recommend, prescribe, or dose any compound. Many of these are research compounds not approved for general human use. Always consult a qualified healthcare provider.